For example, the National Comprehensive Cancer Network (NCCN) guidelines recommend testing for the KRAS alterations as a part of the initial diagnostic check for metastatic colorectal cancer (CRC) [1]. This evidence concerns the gene KRAS and metastatic colorectal cancer.